ANTISENSE THERAPEUTICS LIMITED (ANP)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ANP - ANTISENSE THERAPEUTICS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.01
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.07

22 Sep
2023

-0.001

OPEN

$0.07

-1.41%

HIGH

$0.07

741,640

LOW

$0.07

TARGET
$0.23 228.6% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . KZA . LGP . MAP . MDC . MSB . MVP . MXC . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PNV . PXS . PYC . RAC . RCE . RNO . SPL . TLX . TRP . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
ANP: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx - 1.7 - 1.9 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-1.7
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx-
Book Value Per Share xxxxxxxxxxxxxxx1.5
Net Operating Cash Flow xxxxxxxxxxxxxxx-8.2 M
Net Profit Margin xxxxxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-73.14 %
Return on Invested Capital xxxxxxxxxxxxxxx-72.72 %
Return on Assets xxxxxxxxxxxxxxx-64.51 %
Return on Equity xxxxxxxxxxxxxxx-73.14 %
Return on Total Capital xxxxxxxxxxxxxxx-84.77 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-8.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx11 M
Price To Book Value xxxxxxxxxxxxxxx3.96

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx13 M
Research & Development xxxxxxxxxxxxxxx10 M
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

29/08/2023

1

Speculative Buy

$0.23

228.57%

There were no surprises for Morgans contained within FY23 results for Antisense Therapeutics due to the recent quarterly update.

The analysts note the cash balance has recently been supported by the successful institutional placement and share purchase plan.

The FY24 focus now turns to near-term catalysts such as recruitment milestones, the toxicology study and the Ph2b top-line results.

The Speculative Buy and 23c target are maintained.

FORECAST
Morgans forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -1.90 cents.
Morgans forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -1.30 cents.
Access Stockbroker Research History >

ANP STOCK CHART

FNArena News on ANP

1
FNArena Corporate Results Monitor – 29-08-2023

Aug 29 2023 - Australia
2
Australian Broker Call *Extra* Edition – Jul 25, 2023

Jul 25 2023 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Jun 28, 2023

Jun 28 2023 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Sep 19, 2022

Sep 19 2022 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Apr 28, 2022

Apr 28 2022 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: Cleo Diagnostics

Aug 30 2023 - Small Caps
2
Breaking Boundaries: Medical Psychedelics

Aug 21 2023 - Small Caps
3
Momentum Keeps Building For Avita Medical

Aug 15 2023 - Small Caps
4
Dr Boreham’s Crucible: IDT Australia

Aug 14 2023 - Small Caps
5
Treasure Chest: Less Smooth Road Ahead For CSL

Aug 01 2023 - Treasure Chest
6
Dr Boreham’s Crucible: Telix Pharmaceuticals

Jul 31 2023 - Small Caps
7
Dr Boreham’s Crucible: Arovella Therapeutics

Jul 17 2023 - Small Caps
8
Dr Boreham’s Crucible: PolyNovo

Jul 06 2023 - Small Caps
9
CSL Disappoints But Brokers Retain The Faith

Jun 15 2023 - Australia
10
Dr Boreham’s Crucible: Dimerix

Jun 07 2023 - Small Caps